Argenica Therapeutics Limited (ASX:AGN)
Argenica Therapeutics Limited (ASX:AGN) is commercialising the novel neuroprotective therapeutic ARG-007 to reduce the damaging effects of stroke and other acute CNS injuries.
Drug development is tightly regulated and involves the sequential demonstration of both safety and efficacy of compounds. Argenica is undertaking the required Drug Research and Development Process to progress through to commercialisation. Argenica is completing the pre-clinical safety and toxicity assessments required for entering clinical trials, with the Phase 1 clinical trial currently scheduled for initiation in the second half of 2021.
Argenica was incorporated in 2019 to undertake the development and commercialisation of a novel drug based on the pioneering work of Professor Bruno Meloni and Clinical Professor Neville Knuckey at the University of Western Australia (UWA) and the Perron Institute for Neurological and Translational Science (Perron Institute). The drug, known as ARG-007, a cationic, arginine rich peptide, has neuroprotective properties that has the potential to offer protection to the brain following stroke and other acute central nervous system injuries.